Cyclacel Pharmaceuticals, Inc. (CYCC)

NASDAQ: CYCC · IEX Real-Time Price · USD

1.670

-0.040 (-2.34%)

At close: Jul 19, 2024, 4:00 PM

1.700

+0.030 (1.80%)

Pre-market: Jul 22, 2024, 7:16 AM EDT

Cyclacel Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2001
Revenue	0.45	0.42	0	0	0	0	Upgrade
Gross Profit	0.45	0.42	0	0	0	0	Upgrade
Selling, General & Admin	6.66	6.72	7.38	7.46	5.88	5.02	Upgrade
Research & Development	16.28	19.16	20.27	14.93	4.76	4.66	Upgrade
Operating Expenses	22.94	25.87	27.66	22.39	10.64	9.68	Upgrade
Operating Income	-22.49	-25.45	-27.66	-22.39	-10.64	-9.68	Upgrade
Other Expense / Income	0.24	0.1	-1.74	-0.2	-0.96	-0.56	Upgrade
Pretax Income	-22.73	-25.55	-25.92	-22.19	-9.68	-9.13	Upgrade
Income Tax	-3.03	-3	-4.72	-3.73	-1.24	-1.3	Upgrade
Net Income	-19.7	-22.56	-21.2	-18.46	-8.45	-7.83	Upgrade
Preferred Dividends	0.15	0.2	0.2	0.2	3.98	0.2	Upgrade
Net Income Common	-19.85	-22.76	-21.4	-18.66	-12.42	-8.03	Upgrade
Shares Outstanding (Basic)	1	1	1	1	0	0	Upgrade
Shares Outstanding (Diluted)	-	-	1	1	0	0	Upgrade
Shares Change	57.70%	12.32%	26.10%	145.67%	345.23%	34.95%	Upgrade
EPS (Basic)	-22.05	-26.75	-28.70	-31.35	-51.30	-147.60	Upgrade
EPS (Diluted)	-22.05	-26.75	-28.70	-31.35	-51.30	-147.60	Upgrade
Free Cash Flow	-9.73	-16.12	-20.83	-18.57	-8.03	-9.42	Upgrade
Free Cash Flow Per Share	-7.38	-19.12	-27.77	-31.20	-33.15	-173.13	Upgrade
Gross Margin	100.00%	100.00%	-	-	-	-	Upgrade
Operating Margin	-5008.69%	-6060.24%	-	-	-	-	Upgrade
Profit Margin	-4420.27%	-5418.10%	-	-	-	-	Upgrade
Free Cash Flow Margin	-2167.93%	-3837.62%	-	-	-	-	Upgrade
EBITDA	-22.7	-25.52	-25.88	-22.14	-9.66	-9.11	Upgrade
EBITDA Margin	-5056.12%	-6076.19%	-	-	-	-	Upgrade
Depreciation & Amortization	0.03	0.03	0.03	0.04	0.02	0.02	Upgrade
EBIT	-22.73	-25.55	-25.92	-22.19	-9.68	-9.13	Upgrade
EBIT Margin	-5061.69%	-6083.57%	-	-	-	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).